Navigation Links
Transdel Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
Date:9/2/2009

rget='_new' href="http://www.transdelpharma.com/" target="_new">http://www.transdelpharma.com.

Safe Harbor Statement

Statements made in this release that are not historical in nature constitute forward-looking statements. Forward-looking statements can be identified by the use of words such as "expects," "plans," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Please note that forward-looking statements are based on projections, that these projections involve judgment, and that individual judgments may vary. Moreover, these statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of the Company's future financial results and its ability to raise additional funds to support its operations, its ability to complete the required clinical trials and obtain FDA approval for Ketotransdel, the efficacy and the commercial success of any cosmetic/cosmeceutical products it develops, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
2. Transdel Pharmaceuticals Provides Update on Timing of Results for Phase 3 Study
3. Transdel Pharmaceuticals Enters Into License Agreement with JH Direct, LLC for Cosmeceutical Product
4. Transdel Pharmaceuticals, Inc. Featured on National Broadcast Television
5. Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities
6. Transdel Expands Program to Include Cosmetic/Cosmeceutical Products
7. Transdel Pharmaceuticals Appoints Mr. Lynn Swann, Pro-Football Hall of Famer, ABC Sports Broadcaster, and Former Chairman of the Presidents Council on Physical Fitness and Sports, to Board of Directors
8. Transdel Pharmaceuticals to Present at Cowen and Companys 28th Annual Health Care Conference
9. MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences
10. Lexicon Pharmaceuticals to Present at the Thomas Weisel Partners Healthcare Conference
11. EPIX Pharmaceuticals, Inc. Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered For Sale at the September 30, 2009 Auction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... ... development solutions for drugs, biologics and consumer health products, today welcomed the announcement ... review OPKO’s New Drug Application for a new treatment for chronic kidney disease ...
(Date:8/3/2015)... ... , ... The art of preparing and cooking food comes naturally to some. ... age, Nasreen Zereshki was extremely eager to cook Persian cuisine. Now that she is ... Persian Kitchen with the world. , Since Americans tend to be undereducated about Persian ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) recently ... to deoxycholic acid, which occurs naturally in the body and helps absorb and breakdown ... area of the body. These are invasive procedures and very expensive for most people. ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dignity Health named Dr. Norris A. ... Emergency Room – Gilbert, opening in August. The new facility is licensed under ... West Valley. , “Dr. Baldwin is an excellent leader and will ensure our ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 2Health News:Dignity Health Names Dr. Norris A. Baldwin, Jr. Facility Medical Director of New Freestanding Emergency Room 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... FairWarning, Inc. a provider of healthcare privacy auditing ... titled Addressing Electronic Health Record Privacy ... The Webinar will feature John Wade, ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Tour Shows Dramatic Impact of AIDS on Children, ... Funds for Social Causes, CINCINNATI, Feb. 13 ... Network (TPN), has partnered with World,Vision to produce ... a national tour designed to raise awareness about ...
... Monitoring Committee holds third meeting -, ... Life Sciences,Inc. (TSX: BNC), a research-based, technology-driven ... update on the progress,of its North American ... - trademarked Urocidin - in patients with ...
... Most Fertile ... Throughout Entire Month, PRINCETON, N.J., Feb. 13 Trying to predict ... provide,only a handful of chances to identify the two most fertile days ... most fertile,days: The new FIRST RESPONSE Daily Ovulation Test includes 20 testing,sticks ...
... for heart, pneumonia care, ST. PAUL, Minn., Feb. ... metro area in three key areas of a,national quality ... heart attack, heart failure and pneumonia care, according to,The ... "We,re very proud of the ongoing quality improvement work ...
... GARDENA, Calif., Feb. 13 Consumers today are ... away from,carbs, while other experts say that the ... we take in each day. The answers may ... oldest populations on earth, namely,Japan., Zojirushi ( ...
Cached Medicine News:Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 3Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 2Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 3Health News:New FIRST RESPONSE(R) Home Ovulation Test Takes the Guesswork Out of Conception 2Health News:Busting the Myth, One Bowl at a Time 2
(Date:8/3/2015)... , Aug. 3, 2015 Par Pharmaceutical ... conference call on Friday, August 7, 2015 at 9:00 ... the second quarter ended June 30, 2015.  Par is ... to the public in its filings with the Securities ... available on its website by following the instructions at ...
(Date:8/3/2015)... , Aug. 3, 2015 OmniSeq, LLC ... Institute to the OmniSeq SM Genomic Network.  ... Cancer Institute (RPCI) and announced it was making ... a physician-driven, collaborative approach to genomic diagnostics that ... Cancer Institute is a rapidly expanding, multidisciplinary cancer ...
(Date:8/3/2015)...  Sage Analytics ( www.sageanalytics.com ), the developers of ... systems, announced its sponsorship of the California Cannabis Industry ... number of tickets are available for groups or individuals ... while enjoying an open bar, buffet dinner and hors ... Bay at sunset. With the legislative session ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2
... YORK, April 9, 2008 Intra-Cellular Therapies, ... ongoing development,programs for ITI-007, the Company,s first-in-class ... and ITI-722,a low-dose formulation of ITI-007, which ... respectively. These new data demonstrate,ITI-007 has preclinical ...
... ... - Preliminary Phase I/II results to be presented in June at 2008 ... ... ), a clinical-stage biopharmaceutical company,focused on oncology, announced today that it has advanced CR011-vcMMAE, ...
Cached Medicine Technology:Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 2Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722 3CuraGen Advances CR011-vcMMAE into Phase II 2CuraGen Advances CR011-vcMMAE into Phase II 3CuraGen Advances CR011-vcMMAE into Phase II 4
... HIV-1 Genotyping: The genome of ... in an infected patient, especially in response ... mutations have been shown to render the ... drugs, diminishing the effectiveness of the treatment.,The ...
EIA for Donor Screening. Synthetic peptide Enzyme Immunoassay (EIA) for the detection of antibodies to Human Immunodeficiency Virus Types 1 and/or 2,(HIV-1 and HIV-2) in human serum, plasma or ca...
... The Reveal Rapid HIV-1 Antibody Test (Reveal ... This test detects antibodies in human serum ... by the body in response to HIV ... MedMiras proprietary flow-through membrane technology, and is ...
... The OraQuick ADVANCE ... is a single-use, qualitative ... to Human Immunodeficiency Virus ... Type 2 (HIV-2) in ...
Medicine Products: